AKS-130 is an insulin-Fc fusion protein designed to lower blood glucose levels, without causing clinical hypoglycemia, in order to target the Insulin Receptors in tumor cells. It has been found to downregulate Insulin Receptor expression in models of colorectal cancer and malignant melanoma. It is currently in pre-clinical development.

Back to Pipeline